Windtree Therapeutics’ cardiogenic shock medicine istaroxime rapidly raised systolic blood pressure in patients with the life-threatening condition, meeting the main goal of a phase 2 study and sending the small biotech’s shares climbing nearly 40% as the markets opened Wednesday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,